|
Barbara S. Gibbs
Profile
Barbara Gibbs is of counsel in the firm's Intellectual Property Group where she focuses her practice in drafting patent applications and claims, as well as preparing amendments, responses and appeals to USPTO Office Actions. Ms. Gibbs also prepares patent novelty opinions, due diligence opinions and freedom to practice opinions. Prior to joining Bose McKinney & Evans, she worked as a self-employed patent attorney in West Lafayette, Indiana, focusing on biotechnology and chemistry. She brings more than nine years' experience in patent preparation and prosecution, as well as in patent novelty opinions, infringement and due diligence opinions and appeal briefs, and nearly 20 years of research experience to the firm. She earned her juris doctorate, cum laude, from Wayne State University Law School - Detroit in 2001. Ms. Gibbs received her doctor of philosophy in organic chemistry from The Pennsylvania State University in 1992. She earned her master of science in biochemistry from the Medical College of Virginia - Virginia Commonwealth University in 1983. She received her bachelor of science in chemistry from Wheaton College in 1978. Ms. Gibbs is admitted to practice law in the State of Indiana, before the United States District Courts for the Northern and Southern Districts of Indiana, and is a registered patent attorney.
Education
Wayne State University Law School - Detroit (J.D., cum laude, 2001)
The Pennsylvania State University (Ph.D. in organic chemistry, 1992)
Medical College of Virginia, Virginia Commonwealth University (M.S. in biochemistry, 1983)
Wheaton College (B.S. in chemistry, 1978)
Appearances / Publications
Faculty: Barbara S. Gibbs, Jeffrey Scholten, Karen Zimmerman, Dennis McNamara, Danielle Leonard and Judith Sebolt-Leopold, "Kinetic and Physical Characterization of Two Forms of Farnesyl Protein Transferase" - presented at the 15th Winter Enzyme Mechanism Conference, Naples, Florida, January 1997; Richard A. Gibbs, Todd Zahn, YongQi Mu, Barbara Gibbs, and Judith Sebolt-Leopold, "The Evaluation of Potential Substrates for or Inhibitors of Mammalian Protein-Farnesyl Transferas" - presented at the XVI Midwest Enzyme Chemistry Conference, Chicago, Illinois, October, 1996; Xinggao Fang, Barbara S. Gibbs and James K. Coward, "Synthesis and Evaluation of Synthetic Analogues of Dolichyl-P-P-Chitobiose as Oligosaccharyltransferase Substrates" - presented at the XV Midwest Enzyme Chemistry Conference, Chicago, Illinois, October 1995; Barbara S. Gibbs, Yun-Li Liu and James K. Coward, "Recognition of Peptide Substrates by Yeast Oligosaccharyltransferase" - presented at the ASBMB/DBC-ACS Joint National Meeting, San Francisco, California, May, 1995; Barbara S. Gibbs and James K. Coward, "Kinetic Studies of Yeast Oligosaccharyl Transferase Utilizing Purified Dolichyl-P-P-Oligosaccharide and Labeled Peptide Substrates" - presented at the XIV Midwest Enzyme Chemistry Conference, Chicago, Illinois, October, 1994; Yun-Li Liu, Barbara S. Gibbs and James K. Coward, "Studies on the Enzyme-Catalyzed Glycosylation of Proteins and Peptides: Probing the Limits of Substrate Recognition" - presented at Great Lakes and Central Joint ACS Regional Meeting, Ann Arbor, Michigan, June 1994; Barbara S. Gibbs and James K. Coward, "A Sensitive and Quantitative Assay for Oligosaccharyl Transferase Using Fluorescent and 14C-Labeled Peptide Substrates" - presented at the XIII Midwest Enzyme Chemistry Conference, Chicago, Illinois, October, 1993; B.J. Schuster and S.J. Benkovic, "Photoaffinity Labeling of the Phenylalanine Hydroxylase Active Site" - presented at the 199th ACS National Meeting, Boston, Massachusetts, April, 1990; V.P. Pigiet and B.J. Schuster, "Thioredoxin and a Monothiol Thioredoxin Catalyze Different Steps in the Refolding of Reduced Proteins" - presented at the 76th Annual Meeting of the American Society of Biological Chemists, Washington, DC, June, 1986. Author: Barbara S. Gibbs, Todd J. Zahn, YongQi Mu, Judith S. Sebolt-Leopold and Richard A. Gibbs, "Novel Farnesol and Geranylgeraniol Analogues: A Potential New Class of Anticancer Agents Directed against Protein Prenylation.
|
